Lithium Ion

Lithium Ion

SCHEMBL30366548

Cc1c(C(=O)[O-])sc2c(N3CCOCC3)nc(Cl)nc12.[Li+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 14/20 0.41
MTOR P42345 9/20 0.41
PIK3CD O00329 9/20 0.39
PIK3CB P42338 8/20 0.39
PIK3R1 P27986 2/20 0.38
KDM4E B2RXH2 3/20 0.37
PIK3CG P48736 7/20 0.37
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
PIK3C2A O00443 1/20 0.36
PIK3C2B O00750 1/20 0.36
STK10 O94804 1/20 0.36
PAK4 O96013 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
FGR P09769 1/20 0.36
FER P16591 1/20 0.36
PRKCA P17252 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26079035 0.88 PIK3CA (0.49) PIK3CAMTORPIK3CDPIK3CBPIK3R1
SCHEMBL30366394 0.83 ALDH1A1 (0.48) PIK3CAMTORPIK3CDKDM4EALDH1A1
SCHEMBL26079034 0.83 ALDH1A1 (0.48) PIK3CAMTORPIK3CDKDM4EALDH1A1
SCHEMBL19849051 0.80 SMN1; SMN2 (0.41) PIK3CAMTORPIK3CDPIK3CBPIK3R1
SCHEMBL30366515 0.80 KDM4E (0.41) PIK3CAMTORPIK3CDPIK3CBKDM4E
SCHEMBL26071916 0.80 KDM4E (0.41) PIK3CAMTORPIK3CDPIK3CBKDM4E
SCHEMBL29788273 0.80 PIK3CA (0.40) PIK3CAMTORPIK3CDPIK3CBPIK3R1
SCHEMBL190265 0.80 PIK3CA (0.40) PIK3CAMTORPIK3CDPIK3CBPIK3R1
SCHEMBL1181308 0.78 SMN1; SMN2 (0.40) PIK3CAMTORPIK3CDPIK3CBPIK3R1
SCHEMBL1180546 0.77 PIK3CA (0.47) PIK3CAMTORPIK3CDPIK3CBPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MONASH UNIVERSITY (AU) 2023-10-05 US disclosed
EP-4165045-A1 DUAL KINASE-BROMODOMAIN INHIBITORS Monash University (AU) 2023-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312577-A1 DUAL KINASE-BROMODOMAIN INHIBITORS MAP2K2, BRPF3, BRDT PIK3CA 574/4885MTOR 679/4885PIK3CD 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.